• Survey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from 5.6 to 2.0
• A separate post-hoc analysis of KINECT-PRO™ data showed patient-reported improvement with INGREZZA across all six physical and socio-emotional areas assessed by the Tardive Dyskinesia Impact Scale (TDIS™) among participants reporting impacts to those areas at baseline

SAN DIEGO, Nov. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the release of findings from a new survey showing that adults with tardive dyskinesia (TD) reported fewer disruptions to work and school after starting treatment with INGREZZA® (valbenazine) capsules.1 A separate post-hoc analysis of the KINECT-PRO™ Phase 4 open-label study showed robust patient-reported improvement with INGREZZA across all six physical and socio-emotional areas measured by the Tardive Dyskinesia Impact Scale (TDIS™) among participants who reported impacts in those areas at baseline. The TDIS is the only psychometrically validated tool that measures the burden of TD from a patient's perspective. The findings will be presented at the Neuroscience Education Institute Fall Congress 2026 taking place Nov. 5-8 in Colorado Springs, Colo.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.